Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The next generation supra-annular, self-expanding Evolut FX transcatheter aortic valve (TAV) system was designed to improve catheter deliverability, provide stable and symmetric valve deployment, and assess commissural alignment during the procedure. The impact of these modifications has not been clinically evaluated.
Methods: Procedural information was collected by survey in 2 Stages: Stage I comprised 23 centers with extensive experience with Evolut TAV systems, and Stage II comprised an additional 46 centers with a broad range of balloon- and self-expanding system experience. Operators were to compare the experience with the Evolut FX to the predicate Evolut PRO+ system.
Results: There were 285 cases during Stage I from June 24 to August 12, 2022, and 254 cases during Stage II from August 15 to September 11, 2022. Overall, the cusp overlap technique was used in 88.6 %, and commissural alignment was achieved in 96.1 % of these cases. Compared to implanter's previous experience with the Evolut PRO+ system, less resistance was noted with the Evolut FX system: in 83.0 % of cases during vascular insertion, in 84.7 % of cases while tracking through the vasculature, in 84.4 % of cases while traversing over the arch, and 76.1 % of cases in advancing across the valve. Better symmetry of valve depth was observed in 423 of 525 cases (80.6 %).
Conclusion: Evolut FX system design modifications translated into improvements in catheter deliverability, deployment symmetry and stability, and commissural alignment as assessed by experienced self-expanding and balloon expandable operators.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.carrev.2024.04.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathogenic variants in TMEM184B cause a neurodevelopmental syndrome associated with alteration of metabolic signaling.
Am J Hum Genet
August 2025
Department of Neuroscience, University of Arizona, Tucson, AZ, USA. Electronic address:
Transmembrane protein 184B (TMEM184B) is an endosomal 7-pass transmembrane protein with evolutionarily conserved roles in synaptic structure and axon degeneration. We report six pediatric cases who have de novo heterozygous variants in TMEM184B; five individuals harbor a rare missense variant, and one individual has an mRNA splice site change. This cohort is unified by overlapping neurodevelopmental deficits including developmental delay, corpus callosum hypoplasia, seizures, and/or microcephaly.
View Article and Find Full Text PDFAdvancing TAVR Precision: The Promising Future of Evolut FX and the Optimized Cusp Overlap Technique.
JACC Cardiovasc Interv
August 2025
Vanderbilt University Medical Center, Division of Cardiovascular Medicine, Nashville, Tennessee, USA. Electronic address:
Subclinical Leaflet Thrombosis and Subclinical Aortic Valve Complex Thrombosis in TAVR.
JACC Adv
August 2025
Department of Cardiology, University Hospital of Strasbourg, Strasbourg, France; Research Unit - UR3074 - Translational Cardiovascular Medicine, University of Strasbourg, Strasbourg, France; GERCA (Groupe pour l'Enseignement et la Recherche Cardiologique en Alsace), Strasbourg, France; Hanoï Medica
Subclinical leaflet thrombosis (SLT) following transcatheter aortic valve replacement occurs in 10% to 15% of patients at 1 month and up to 30% by 1 year, extending to perivalvular structures as subclinical aortic valve-complex thrombosis. We review contributing factors to SLT, including valve-specific parameters such as flow dynamics in the native sinus and neosinus, prosthesis sizing, deployment symmetry, implant depth, and commissural alignment; the persistent metabolic activity of retained calcified leaflets; and the impact of antithrombotic therapy on SLT incidence. Although oral anticoagulation reduces imaging-detected SLT, it increases bleeding and mortality.
View Article and Find Full Text PDFIdeal Navitor Implant Depth for Redo-TAVR Feasibility and Coronary Access: A CT Simulation Study.
JACC Adv
August 2025
Department of Cardiovascular Surgery, Mount Sinai Health System, New York, New York, USA. Electronic address:
Background: The impact of implant depth of the Abbott Navitor intra-annular, self-expanding valve on redo-transcatheter aortic valve replacement (TAVR) feasibility is unknown.
Objectives: The authors sought to determine the feasibility of redo-TAVR and coronary access with Edwards Sapien 3 (S3) valve after initial Navitor valve, based on various implant depths on computed tomography (CT) simulation.
Methods: Using 2050 pre-TAVR CTs of patients with native aortic stenosis, initial Navitor TAVR simulations were done at 3 implant depths (0 mm, 3 mm, and 5 mm), with frame expansion assumed at native annular dimensions and commissural alignment not achievable.